The FDA granted orphan drug designation to cintredekin besudotox for glioblastoma, supporting further research for this ...
One patient has glioblastoma multiforme (GBM), and the other patient has advanced hepatocellular carcinoma (HCC) treated in ...
In May 2023, Georgina Maynard was diagnosed with a brain tumour and given 12 to 18 months to live. More than two years on, ...
Precision NeuroMed (PNM), a clinical-stage biotechnology company pioneering advanced drug delivery technologies for central nervous system (CNS) diseases, today announced that the U.S. Food and Drug ...
QIMR Berghofer biotechnology spin-out company, Cyteph Pty Ltd , has successfully completed recruitment for its first-in-human ...
BOSTON--(BUSINESS WIRE)--BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced that patients have been initially dosed in its Phase 2 ...
BEIJING & BURLINGTON, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and ...
Minister of State for Health and Social Welfare, Dr. Iziaq Salako, has directed key federal research institutions to channel ...
Phase I/II study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM) or gliosarcoma No significant financial ...
Half of patients with GBM present with headaches at diagnosis, which is attributed to increases in intracranial pressure (Table 2). 11 Papilledema, now rarely seen because imaging is typically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback